Literature DB >> 25265235

Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.

Sandra E Dross1, Steve S Rossi, Ingrid A Beck, Mark A Micek, Ana Judith Blanco, Kristy D Seidel, Pablo Montoya, Edmund V Capparelli, Lisa M Frenkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25265235      PMCID： PMC4332529          DOI： 10.1097/QAD.0000000000000451

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.

Authors:  Mark A Micek; Ana Judith Blanco; Ingrid A Beck; Sandra Dross; Laurinda Matunha; Pablo Montoya; Kristy Seidel; Soren Gantt; Eduardo Matediane; Lilia Jamisse; Stephen Gloyd; Lisa M Frenkel
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

2.  Development of esophageal peristalsis in preterm and term neonates.

Authors:  Annamaria Staiano; Gabriella Boccia; Gennaro Salvia; Donato Zappulli; Ray E Clouse
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

3.  Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.

Authors:  M Mirochnick; T Fenton; P Gagnier; J Pav; M Gwynne; S Siminski; R S Sperling; K Beckerman; E Jimenez; R Yogev; S A Spector; J L Sullivan
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

4.  Nevirapine concentrations in newborns receiving an extended prophylactic regimen.

Authors:  Mark Mirochnick; Karin Nielsen-Saines; Jose Henrique Pilotto; Jorge Pinto; Eleanor Jiménez; Valdilea G Veloso; Teresa Parsons; D Heather Watts; Jack Moye; Lynne M Mofenson; Margaret Camarca; Yvonne Bryson
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731
  4 in total
  2 in total

1.  Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.

Authors:  Taimour Langaee; Mohammad H Al-Shaer; Yan Gong; Elizabeth Lima; Sampson Antwi; Anthony Enimil; Albert Dompreh; Hongmei Yang; Wael A Alghamdi; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Infect Genet Evol       Date:  2021-04-08       Impact factor: 3.342

2.  Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

Authors:  Theodore D Ruel; Edmund V Capparelli; Camlin Tierney; Bryan S Nelson; Anne Coletti; Yvonne Bryson; Mark F Cotton; Stephen A Spector; Mark Mirochnick; Rebecca LeBlanc; Christina Reding; Bonnie Zimmer; Deborah Persaud; Mutsa Bwakura-Dangarembizi; Kimesh L Naidoo; Rohan Hazra; Patrick Jean-Philippe; Ellen G Chadwick
Journal:  Lancet HIV       Date:  2020-11-23       Impact factor: 12.767
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.